Advanced Biomed Inc.
ADVBNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ADVB. That does not mean none is planned.
Get an email about ADVB's next catalysts
Track Advanced Biomed (ADVB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
ADVB Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
SPARC0921
Spasticity
SDN-037
Inflammation and Pain Associated With Ocular Surgery
Brimonidine Tartrate Ophthalmic Suspension
Open Angle Glaucoma
SPARC1104 modified dose regimen I
Spasticity
SPARC0913
Open Angle Glaucoma
SPARC0912
Open Angle Glaucoma
SPARC1102 I
Allergic Conjunctivitis
SPARC1310 I
Seasonal Allergic Rhinitis
Vodobatinib (K0706) capsules
Healthy (For Part A)
SPARC1316 Dose 1
Asthma
SPARC1103 low dose
Spasticity
SPARC1203
Allergic Rhinitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SPARC0921 | Phase 3 | Spasticity | - | - |
SDN-037 | Phase 3 | Inflammation and Pain Associated With Ocular Surgery | - | - |
Brimonidine Tartrate Ophthalmic Suspension | Phase 3 | Open Angle Glaucoma | - | - |
SPARC1104 modified dose regimen I | Phase 3 | Spasticity | - | - |
SPARC0913 | Phase 3 | Open Angle Glaucoma | - | - |
SPARC0912 | Phase 3 | Open Angle Glaucoma | - | - |
SPARC1102 I | Phase 2 | Allergic Conjunctivitis | - | - |
SPARC1310 I | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Vodobatinib (K0706) capsules | Phase 2 | Healthy (For Part A) | - | - |
SPARC1316 Dose 1 | Phase 2 | Asthma | - | - |
SPARC1103 low dose | Phase 2 | Spasticity | - | - |
SPARC1203 | Phase 2 | Allergic Rhinitis | - | - |
Frequently asked questions
What is in Advanced Biomed Inc.'s drug pipeline?β
CatalystAlert tracks 12 drug candidates in Advanced Biomed Inc.'s (ADVB) pipeline across Phase 3, Phase 2. Its lead program is Brimonidine Tartrate Ophthalmic Suspension (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Advanced Biomed Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Advanced Biomed Inc. (ADVB) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ADVB biotech catalysts?β
Add ADVB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Advanced Biomed Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
